Warhound Secures $200 Million to Build Genetically Enhanced Military Dogs

Warhound has emerged from stealth mode with a $200 million funding round, a sum that values the company at $1.2 billion. The new venture, which focuses on engineering war dogs for the U.S. military, law enforcement, and emergency response teams, has attracted significant investment from major players in the tech and defense sectors. Investors in the round include Sequoia, 8VC, Corner Ventures, and In-Q-Tel, a venture firm with backing from the CIA and other U.S. intelligence agencies. This financial boost signals strong confidence in the company's ability to redefine how working dogs are bred and equipped for duty.

The primary motivation behind Warhound is a critical gap in the current supply chain for military working dogs. According to the company's launch announcement, more than 80 percent of the U.S. military's working dogs are imported from Europe. Furthermore, fewer than half of those imported animals are deemed fit for service upon arrival. This reliance on foreign sources highlights a dwindling domestic supply of dogs capable of performing dangerous tasks such as bomb detection and search operations. Warhound seeks to change this dynamic by creating a new type of dog engineered specifically for demanding missions.

The concept originated from a meeting between Ben Lamm, co-founder of Colossal Biosciences, and Palmer Luckey, the founder of Anduril. The two connected about a year ago at a conference, where Luckey expressed concern over the state of military working dogs. Lamm subsequently researched breeding practices and discovered that many dogs fail training due to inherited health issues. These problems include poor eyesight, hip dysplasia, muscle atrophy, and a high predisposition to cancer. Lamm believed that genetic engineering could address these flaws by enhancing health, longevity, speed, and olfactory capabilities.

To achieve these goals, Warhound is collaborating with Colossal Biosciences, which licenses its technology to the new venture. The team has established a biobank containing cell lines from top-performing working dog breeds, specifically the Belgian Malinois and German Shepherd. By editing these genes, the company plans to add traits that improve performance while removing those that lead to health complications. Lamm described this process as creating a new type of dog suited for the rigors of military service. Colossal, known for its de-extinction projects involving animals like the mammoth, uses AI and gene cloning technology to support this effort.

Anduril plays a complementary role in the project by providing the hardware and software that will assist the dogs in the field. The defense technology company will supply gear such as protection vests and goggles designed to improve situational awareness for both the animals and their handlers. Lamm explained that these devices could include bulletproof vests equipped with data sensors that transmit information back to humans. This technology aims to make the dogs safer and more effective in the line of duty, enhancing their capabilities beyond their biological modifications.

While Palmer Luckey is a partner in the venture, he does not own equity in the company. Instead, Colossal owns the equity and supports the business through its technology licensing. Viagen, another company owned by Colossal, will partner with Warhound to handle the actual cloning of the dogs. Lamm noted that Viagen's technology offers a high cloning success rate, which is also used in Colossal's programs to protect endangered species. The first batch of dogs is currently being cloned and incubated, with births expected early next year. The company hopes to have these animals in service within two years.

Warhound has not yet determined the price it will charge for these engineered dogs, but it expects to sell to a variety of government and law enforcement entities. These potential buyers include the Department of Defense, military service groups, police forces, and first responders. In terms of regulatory approval, Lamm stated that the company has briefed numerous government groups about the business model. Regarding civilian safety, Lamm assured that each dog will undergo training similar to any standard military working dog and will be managed by the entity that purchases it.

The American Humane Society is involved in the project to help certify Warhound's training program. The organization stated that it is grounded in science and ethics and is pleased to be invited to the table. The Society aims to ensure that the animals in Warhound's care are treated humanely. Additionally, there is a hope that when these new military dogs eventually retire, they will be placed in the Society's Military Working Dog Reunification Program or another initiative designed to help retired dogs find homes.

The collaboration between Colossal and Anduril represents a significant step in the integration of biotechnology and defense hardware. By combining genetic enhancement with advanced digital gear, Warhound aims to create a more resilient and capable workforce of animal partners. The company plans to begin operations soon, with the first cloned dogs expected to be born in the coming year.